FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Clay Siegall

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Concepts & Ideas

Molecular Sequence Data

Disorders

Procedures

Neoplasm Transplantation

Co-author Network

Publications

TOP 3
Carolyn J Henry; Michael S Buss; Ingegerd Hellström; Karl Erik Hellström; William G Brewer; Jeffrey N Bryan; Clay B Siegall
Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Che-Leung Law; Charles G Cerveny; Kristine A Gordon; Kerry Klussman; Bruce J Mixan; Dana F Chace; Damon L Meyer; Svetlana O Doronina; Clay B Siegall; Joseph A Francisco; Peter D Senter; Alan F Wahl
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Joseph A Francisco; Charles G Cerveny; Damon L Meyer; Bruce J Mixan; Kerry Klussman; Dana F Chace; Starr X Rejniak; Kristine A Gordon; Ron DeBlanc; Brian E Toki; Che-Leung Law; Svetlana O Doronina; Clay B Siegall; Peter D Senter; Alan F Wahl
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Clay Siegall (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: Carolyn J Henry; Michael S Buss; Ingegerd Hellström; Karl Erik Hellström; William G Brewer; Jeffrey N Bryan; Clay B Siegall
Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):751-5.
2004: Che-Leung Law; Charles G Cerveny; Kristine A Gordon; Kerry Klussman; Bruce J Mixan; Dana F Chace; Damon L Meyer; Svetlana O Doronina; Clay B Siegall; Joseph A Francisco; Peter D Senter; Alan F Wahl
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(23):7842-51.
2003: Joseph A Francisco; Charles G Cerveny; Damon L Meyer; Bruce J Mixan; Kerry Klussman; Dana F Chace; Starr X Rejniak; Kristine A Gordon; Ron DeBlanc; Brian E Toki; Che-Leung Law; Svetlana O Doronina; Clay B Siegall; Peter D Senter; Alan F Wahl
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Blood 2003;102(4):1458-65.
2003: Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Nature biotechnology 2003;21(7):778-84.
2002: James A Posey; Muhammad B Khazaeli; Michael A Bookman; Anahit Nowrouzi; William E Grizzle; Jennifer Thornton; Delicia E Carey; Jennifer M Lorenz; Amy P Sing; Clay B Siegall; Albert F LoBuglio; Mansoor N Saleh
A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(10):3092-9.
2002: Alan F Wahl; Kerry Klussman; Jennifer D Thompson; Judy H Chen; Leigh V Francisco; Grant Risdon; Dana F Chace; Clay B Siegall; Joseph A Francisco
The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Cancer research 2002;62(13):3736-42.
2002: Jamie L Szocinski; Annette Khaled; Julie Hixon; Douglas Halverson; Satoshi Funakoshi; William C Fanslow; Ann Boyd; Dennis D Taub; Scott K Durum; Clay B Siegall; Dan Longo; William Murphy
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax.
Blood 2002;100(1):217-23.
2001: Alan F Wahl; K L Donaldson; Bruce J Mixan; P A Trail; Clay B Siegall
Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
International journal of cancer. Journal international du cancer 2001;93(4):590-600.
2000: Joseph A Francisco; K L Donaldson; Dana F Chace; Clay B Siegall; Alan F Wahl
Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.
Cancer research 2000;60(12):3225-31.
1999: H G Haggerty; W A Warner; C R Comereski; W M Peden; L E Mezza; B D Damle; Clay B Siegall; T J Davidson
BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
Toxicologic pathology 1999;27(1):87-94.
1998: Joseph A Francisco; Clay B Siegall
Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies.
Leukemia & lymphoma 1998;30(3-4):237-45.
1998: Bruce J Mixan; B D Cohen; S S Bacus; HP Fell; Clay B Siegall
Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity.
Oncogene 1998;16(9):1209-15.
1998: D K Fryxell; SL Gawlak; R W Dodge; Clay B Siegall
Identification of a specific tyrosine residue in Bryodin 1 distinct from the active site but required for full catalytic and cytotoxic activity.
Protein science : a publication of the Protein Society 1998;7(2):318-24.
1998: B D Cohen; Clay B Siegall; S Bacus; L Foy; J M Green; Ingegerd Hellström; Karl Erik Hellström; HP Fell
Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma.
Biochemical Society symposium 1998;63():199-210.
1997: Clay B Siegall; H G Haggerty; G L Warner; Dana F Chace; Bruce J Mixan; Peter Linsley; T Davidson
Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(10):5168-73.
1997: Joseph A Francisco; SL Gawlak; Clay B Siegall
Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1.
The Journal of biological chemistry 1997;272(39):24165-9.
1997: Joseph A Francisco; SL Gawlak; M Miller; J Bathe; D Russell; Dana F Chace; Bruce J Mixan; L Zhao; HP Fell; Clay B Siegall
Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture.
Bioconjugate chemistry 1997;8(5):708-13.
1997: Joseph A Francisco; G J Schreiber; C R Comereski; L E Mezza; G L Warner; T J Davidson; Jeffrey A Ledbetter; Clay B Siegall
In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.
Blood 1997;89(12):4493-500.
1997: SL Gawlak; M Neubauer; H E Klei; C Y Chang; H M Einspahr; Clay B Siegall
Molecular, biological, and preliminary structural analysis of recombinant bryodin 1, a ribosome-inactivating protein from the plant Bryonia dioica.
Biochemistry 1997;36(11):3095-103.
1997: Clay B Siegall; D Liggitt; Dana F Chace; Bruce J Mixan; J Sugai; T Davidson; M Steinitz
Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):339-45.
1997: Jeffrey A Ledbetter; Joseph A Francisco; Clay B Siegall; L K Gilliland; Diane L Hollenbaugh; Alejandro Aruffo; Anthony W Siadak; N Mischel-Petty; LS Grosmaire; M L Gordon; T J Brown; P Moran-Davis; Robert S Mittler; Peter Kiener; Steven G Nadler
Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5.
Critical reviews in immunology 1997;17(5-6):427-35.
1996: Joseph A Francisco; Peter Kiener; P Moran-Davis; Jeffrey A Ledbetter; Clay B Siegall
Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(4):1652-8.
1996: Clay B Siegall
Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1996;140():51-60.
1996: Ingegerd Hellström; Pamela A Trail; Clay B Siegall; Raymond A Firestone; Karl Erik Hellström
Immunoconjugates and immunotoxins for therapy of solid tumors.
Cancer chemotherapy and pharmacology 1996;38 Suppl():S35-6.
1995: Clay B Siegall
Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
Seminars in cancer biology 1995;6(5):289-95.
1995: Joseph A Francisco; L K Gilliland; M R Stebbins; N A Norris; Jeffrey A Ledbetter; Clay B Siegall
Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
Cancer research 1995;55(14):3099-104.
1995: E A Wolff; I Hellström; Dana F Chace; K E Hellström; Clay B Siegall
Antitumour activity of a melanoma-specific immunotoxin, ME20-LysPE40.
Therapeutic immunology 1995;2(3):137-45.
1995: Clay B Siegall; Sarah S Bacus; B D Cohen; Greg Plowman; Bruce J Mixan; Dana F Chace; D M Chin; A Goetze; J M Green; I Hellström
HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.
The Journal of biological chemistry 1995;270(13):7625-30.
1995: Ingegerd Hellström; Karl Erik Hellström; Clay B Siegall; Pamela A Trail
Immunoconjugates and immunotoxins for therapy of carcinomas.
Advances in pharmacology (San Diego, Calif.) 1995;33():349-88.
1994: Clay B Siegall; D Liggitt; Dana F Chace; Mark Tepper; H P Fell
Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(20):9514-8.
1994: Clay B Siegall; SL Gawlak; Dana F Chace; E A Wolff; Bruce J Mixan; H Marquardt
Characterization of ribosome-inactivating proteins isolated from Bryonia dioica and their utility as carcinoma-reactive immunoconjugates.
Bioconjugate chemistry 1994;5(5):423-9.
1994: Clay B Siegall
Targeted toxins as anticancer agents.
Cancer 1994;74(3 Suppl):1006-12.
1994: Clay B Siegall; Dana F Chace; Bruce J Mixan; U Garrigues; H Wan; L Paul; E Wolff; I Hellström; K E Hellström
In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(5):2377-84.
1994: Clay B Siegall; SL Gawlak; Dana F Chace; J R Merwin; Ira Pastan
In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins.
Bioconjugate chemistry 1994;5(1):77-83.
1993: SL Gawlak; Ira Pastan; Clay B Siegall
Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin.
Bioconjugate chemistry 1993;4(6):483-9.
1993: P N Friedman; Dana F Chace; Pamela A Trail; Clay B Siegall
Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(7):3054-61.
1993: P N Friedman; S J McAndrew; SL Gawlak; Dana F Chace; Pamela A Trail; J P Brown; Clay B Siegall
BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
Cancer research 1993;53(2):334-9.
1992: J R Merwin; M J Lynch; J A Madri; Ira Pastan; Clay B Siegall
Acidic fibroblast growth factor-Pseudomonas exotoxin chimeric protein elicits antiangiogenic effects on endothelial cells.
Cancer research 1992;52(18):4995-5001.
1992: Clay B Siegall; SL Gawlak; J J Chin; M E Zoeckler; K F Kadow; J P Brown; G R Braslawsky
Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
Bioconjugate chemistry 1992;3(4):302-7.